WO2023031673 - TREATING LONG COVID-19 WITH UROLITHINS
National phase entry:
Publication Number
WO/2023/031673
Publication Date
09.03.2023
International Application No.
PCT/IB2022/000597
International Filing Date
30.08.2022
Title **
[English]
TREATING LONG COVID-19 WITH UROLITHINS
[French]
TRAITEMENT DE LA COVID-19 LONGUE AU MOYEN D'UROLITHINES
Applicants **
AMAZENTIS SA
EPFL Innovation Park
Bâtiment C
1015 Lausanne, CH
Inventors
RINSCH, Christopher, L.
60 Rue de Lausanne
1110 Morges, CH
SINGH, Anurag
Chemin de Montremoen 5
1024 Crissier, CH
D'AMICO, Davide
Chemin des Cotes, 10
1020 Renens, CH
Priority Data
63/238,659
30.08.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2027 | |
| EPO | Filing, Examination | 14999 | |
| Japan | Filing | 587 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 8110 |
Total: 26297 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention provides methods useful for treating post-viral illness, including long COVID-19, in a subject afflicted therewith comprising administering to the subject an urolithin.[French]
L'invention concerne des méthodes utiles pour traiter une maladie post-virale, notamment la COVID-19 longue, chez un sujet atteint de celle-ci, comprenant l'administration au sujet d'une urolithine.